HK1178538A1 - Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals - 3-- - Google Patents

Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals - 3--

Info

Publication number
HK1178538A1
HK1178538A1 HK13106299.0A HK13106299A HK1178538A1 HK 1178538 A1 HK1178538 A1 HK 1178538A1 HK 13106299 A HK13106299 A HK 13106299A HK 1178538 A1 HK1178538 A1 HK 1178538A1
Authority
HK
Hong Kong
Prior art keywords
heteroaroylamino
pharmaceuticals
substituted
oxygen
propionic acid
Prior art date
Application number
HK13106299.0A
Other languages
English (en)
Chinese (zh)
Inventor
Sven Ruf
Josef Pernerstorfer
Thorsten Sadowski
Georg Horstick
Herman Schreuder
Christian Buning
Thomas Olpp
Bodo Scheiper
Klaus Wirth
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of HK1178538A1 publication Critical patent/HK1178538A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK13106299.0A 2010-01-26 2013-05-28 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals - 3-- HK1178538A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305080 2010-01-26
US30911910P 2010-03-01 2010-03-01
PCT/EP2011/051038 WO2011092187A1 (fr) 2010-01-26 2011-01-26 Dérivés d'acide 3-hétéroaroylamino-propionique à substitution oxygène et leur utilisation comme produits pharmaceutiques

Publications (1)

Publication Number Publication Date
HK1178538A1 true HK1178538A1 (en) 2013-09-13

Family

ID=42035666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13106299.0A HK1178538A1 (en) 2010-01-26 2013-05-28 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals - 3--

Country Status (30)

Country Link
US (2) US8664257B2 (fr)
EP (2) EP2826772A1 (fr)
JP (1) JP5736390B2 (fr)
KR (1) KR101764608B1 (fr)
CN (1) CN102884052B (fr)
AR (1) AR079967A1 (fr)
AU (1) AU2011209333B2 (fr)
BR (1) BR112012018253A2 (fr)
CA (1) CA2784571A1 (fr)
CL (1) CL2012002069A1 (fr)
CO (1) CO6660462A2 (fr)
DK (1) DK2528902T3 (fr)
ES (1) ES2530073T3 (fr)
HK (1) HK1178538A1 (fr)
HR (1) HRP20150075T1 (fr)
IL (1) IL220998A0 (fr)
MA (1) MA33948B1 (fr)
MX (1) MX2012008635A (fr)
MY (1) MY156569A (fr)
NZ (1) NZ601307A (fr)
PL (1) PL2528902T3 (fr)
PT (1) PT2528902E (fr)
RS (1) RS53789B1 (fr)
RU (1) RU2561126C2 (fr)
SG (1) SG182659A1 (fr)
SI (1) SI2528902T1 (fr)
TW (1) TWI532725B (fr)
UY (1) UY33200A (fr)
WO (1) WO2011092187A1 (fr)
ZA (1) ZA201204414B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451796B1 (fr) 2009-07-08 2013-04-17 Dermira (Canada), Inc. Analogues de tofa utiles dans le traitement de troubles ou états dermatologiques
CA2835216A1 (fr) * 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de neprilysine
WO2012166390A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de néprilysine
WO2012166389A1 (fr) 2011-05-31 2012-12-06 Theravance, Inc. Inhibiteurs de néprilysine
SI2736888T1 (sl) 2011-07-26 2016-02-29 Sanofi Derivati 3-heteroaroilamino-propionske kisline in njihova uporaba kot farmacevtska sredstva
MY162786A (en) 2011-07-26 2017-07-14 Sanofi Sa Substituted 3-thiazoloamino-propionic acid derivatives and their use as pharmaceuticals
JO3215B1 (ar) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014053533A1 (fr) 2012-10-05 2014-04-10 Sanofi Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire
SG11201506190QA (en) 2013-03-28 2015-09-29 Sanofi Sa Biaryl-propionic acid derivatives and their use as pharmaceuticals
MX2015013799A (es) 2013-03-28 2016-02-16 Sanofi Sa Derivados de acido-biaril-propionico y su uso como productos farmaceuticos.
EP3061754A4 (fr) 2013-10-23 2017-03-22 Takeda Pharmaceutical Company Limited Composé hétérocyclique
AU2017223132B2 (en) 2016-02-23 2019-12-05 Pfizer Inc. 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE226883C (de) 1908-12-03 1910-10-11 Draegerwerk Ag UEberdruckoperationsapparat, bei welchem der Lunge des Patienten durch Mund und Nase die Atmungsluft unter moeglichst gleichbleibenden, geringem UEberdruck zugefuehrt wird
DD226883A1 (de) 1984-07-30 1985-09-04 Neubauer T Paedagog Hochschule Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen
US5258397A (en) 1988-11-30 1993-11-02 Novapharme 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions
EP0700394B1 (fr) 1993-05-27 1998-04-01 Shell Internationale Researchmaatschappij B.V. Herbicides derives du thiazole
JP2000169453A (ja) 1998-09-30 2000-06-20 Mitsubishi Chemicals Corp １―フェニルピラゾ―ル―３―カルボキサミド誘導体、その中間体およびこれを有効成分とする農薬
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US20040072802A1 (en) 2002-10-09 2004-04-15 Jingwu Duan Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
BR0317659A (pt) 2002-12-23 2005-12-06 Aventis Pharma Gmbh Derivados de pirazol como inibidores de fator xa
JP2005145839A (ja) * 2003-11-12 2005-06-09 Japan Science & Technology Agency 新規なカテプシンａ阻害剤
BRPI0513677B8 (pt) * 2004-07-30 2021-05-25 Exelixis Inc derivados de pirrol como agentes farmacêuticos
CA2593156C (fr) 2005-01-10 2015-05-05 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques
US20090209522A1 (en) 2005-06-28 2009-08-20 Graham Andrew Showell Heterocyclic Non-Peptide GNRH Antagonists
CN101104602A (zh) * 2006-07-12 2008-01-16 赛诺菲-安万特 N-[(1,5-二苯基-1h-吡唑-3-基)甲基]磺酰胺衍生物其制备、用途
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
CL2008001163A1 (es) 2007-04-27 2008-12-19 Takeda Pharmaceutical Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.
KR20100091255A (ko) * 2007-12-10 2010-08-18 7티엠 파마 에이/에스 카나비노이드 수용체 조절자
JP5504171B2 (ja) * 2007-12-26 2014-05-28 サノフイ Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
JP5560202B2 (ja) 2007-12-26 2014-07-23 サノフイ Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体
ATE555107T1 (de) 2008-02-21 2012-05-15 Actelion Pharmaceuticals Ltd 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI1011657A2 (pt) * 2009-05-28 2019-04-16 Novartis Ag derivados aminopropiônicos substituídos como inibidores de neprilisina

Also Published As

Publication number Publication date
DK2528902T3 (en) 2015-02-09
TWI532725B (zh) 2016-05-11
EP2528902B1 (fr) 2014-11-12
AU2011209333B2 (en) 2014-12-11
KR20120118050A (ko) 2012-10-25
US8664257B2 (en) 2014-03-04
CO6660462A2 (es) 2013-04-30
UY33200A (es) 2011-08-31
PT2528902E (pt) 2015-01-14
MY156569A (en) 2016-03-15
WO2011092187A1 (fr) 2011-08-04
SG182659A1 (en) 2012-08-30
MA33948B1 (fr) 2013-01-02
MX2012008635A (es) 2012-08-23
ZA201204414B (en) 2013-02-27
CN102884052A (zh) 2013-01-16
EP2528902A1 (fr) 2012-12-05
HRP20150075T1 (hr) 2015-04-10
JP2013518077A (ja) 2013-05-20
SI2528902T1 (sl) 2015-02-27
CA2784571A1 (fr) 2011-08-04
KR101764608B1 (ko) 2017-08-03
US20140128616A1 (en) 2014-05-08
IL220998A0 (en) 2012-09-24
RU2561126C2 (ru) 2015-08-20
JP5736390B2 (ja) 2015-06-17
AU2011209333A1 (en) 2012-08-09
NZ601307A (en) 2014-06-27
TW201130802A (en) 2011-09-16
US20130046004A1 (en) 2013-02-21
BR112012018253A2 (pt) 2023-11-21
CL2012002069A1 (es) 2012-10-19
EP2826772A1 (fr) 2015-01-21
AR079967A1 (es) 2012-02-29
CN102884052B (zh) 2015-10-21
RU2012136473A (ru) 2014-03-10
PL2528902T3 (pl) 2015-04-30
RS53789B1 (en) 2015-06-30
ES2530073T3 (es) 2015-02-26

Similar Documents

Publication Publication Date Title
HUS2100032I1 (hu) Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk
IL250259B (en) Preparations containing ursolic acid or its derivative and their uses
HK1192879A1 (zh) 取代的 -苄基環烷基羧酸及其用途
HK1178538A1 (en) Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals - 3--
IL221511A (en) Arilatriazolones associated with bis aryl and their use
ZA201208173B (en) Peptices and their use
IL250370A0 (en) Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals
ZA201303773B (en) Compounds and their use
EP2575453A4 (fr) Composés oligo-benzamide et leur utilisation
PL2521445T3 (pl) Preparat i jego zastosowanie
EP2636666A4 (fr) Dérivé de l'acide trans-2-décénoïque et médicament associé
PL2648715T3 (pl) Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie
ZA201205565B (en) Ester compound and use thereof
GB201020848D0 (en) Compounds and their use
GB201018028D0 (en) Compounds and their use
GB201017822D0 (en) Compounds and their use
GB201005511D0 (en) Compounds and their use
GB201002337D0 (en) Compounds and their use
GB201000309D0 (en) Compounds and their use
GB201000308D0 (en) Compounds and their use
GB201000307D0 (en) Compounds and their use
GB201000305D0 (en) Compounds and their use
GB201005729D0 (en) End effectors and parts thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190121